Elizabeth D. Tullis

机构：St. Michael's Hospital, Cystic Fibrosis Canada, St Michael's Hospital

发表论文 244 篇 · 总被引 18592 次 · h-index 60

代表论文

• Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele (2023 · American Journal of Respiratory and Critical Care Medicine · 被引 143)
• Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials (2025 · The Lancet Respiratory Medicine · 被引 115)
• Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study (2023 · European Respiratory Journal · 被引 96)
• Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials (2023 · The Lancet Respiratory Medicine · 被引 74)
• Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 56)
• Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events (2023 · American Journal of Respiratory and Critical Care Medicine · 被引 56)